Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid-related therapeutic products in Taiwan. Its offerings include RenehaVis and SportVis, injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a hyaluronic acid-based medical device for treating and preventing ulcerative colitis in inflammatory bowel disease; and GAF, a gel for anal fissure healing. The company is also developing IBD98-M, an oral capsule in Phase IIa for ulcerative colitis; CA102N, a receptor-targeted chemotherapy in Phase II for metastatic colorectal cancer, pre-clinical for pancreatic ductal adenocarcinoma, and discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate in pre-clinical for Alzheimer's disease; AMD112, a non-invasive HA-conjugated small molecule therapy in pre-clinical for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, an HA-derived nanoparticle platform in discovery stage. Additionally, it engages in general investment, development and sale of medical devices, biotechnology services, and patent applications for pharmaceutical products. Founded in 2001, the company is headquartered in Taipei, Taiwan.